Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
First-in-human study starts include radioligands from Akiram and Philogen.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
